摘要
目的 比较尼妥珠单抗联合同步放化疗与贝伐珠单抗联合同步放化疗治疗局部晚期宫颈癌的近期疗效及不良反应。方法 收集2020年9月1日—2021年12月31日病理类型为鳞状细胞癌的100例局晚期宫颈癌患者,分为对照组(同步放化疗组)、尼妥组(尼妥珠单抗联合同步放化疗组)与贝伐组(贝伐珠单抗联合同步放化疗组)。比较三组患者的近期治疗总有效率、治疗前后肿瘤体积的变化、治疗前后血清鳞状细胞癌抗原(SCC)水平及治疗后不良反应。结果 尼妥组、贝伐组与对照组的近期治疗总有效率分别为90.3%、87.2%及60.0%,尼妥组和贝伐组治疗总有效率均显著高于对照组,差异均有统计学意义(P<0.001),尼妥组与贝伐组治疗总有效率无统计学差异(P>0.05);尼妥组与贝伐组治疗后肿瘤体积缩小程度以及SCC降低的程度均高于对照组(P<0.05),两组间无统计学差异(P>0.05)。贝伐组高血压发生率为33.4%,明显高于对照组(10.0%)和尼妥组(12.9%)(P<0.05),尼妥组与对照组高血压发生率无统计学差异(P>0.05);三组除高血压外的不良反应发生率均无统计学差异(P>0.05)。结论 尼妥珠单抗联合同步放化疗和贝伐珠单抗联合同步放化疗均可以提高局部晚期宫颈癌的近期疗效,有效缩小肿瘤体积和抑制肿瘤标志物表达,效果均优于单纯同步放化疗。尼妥珠单抗相较于贝伐珠单抗,不良反应更少,对于局部晚期宫颈癌患者来说,尼妥珠单联合同步放化疗安全性更为可靠。
Objective The objective of this study was to compare the short-term efficacy and adverse reactions of nituzumab combined with synchronous radiotherapy and chemotherapy and bevacizumab combined with synchronous radiotherapy and chemotherapy in the treatment of locally advanced cervical cancer.Methods A total of 100 locally advanced cervical cancer patients with pathological type of squamous cell carcinoma were collected from 1 September 2020 to 31 December 2021.They were divided into a control group(synchronous radiotherapy and chemotherapy group),a nituzumab group(nituzumab combined synchronous radiotherapy group)and a bevacizumab group(bevacizumab combined synchronous radiotherapy and chemotherapy group).The total effective rate of short-term treatment,changes in tumor volume before and after treatment,serum squamous cell carcinoma antigen(SCC)levels before and after treatment,and adverse reactions after treatment were compared among patients of the three groups.Results The short-term total effective rates of the Nitro group,Bevar group and control group were 90.3%,87.2%and 60.0%,respectively.The total effective rates of the Nitro and Bevar groups were significantly higher than those of the control group,and the differences were statistically significant(P<0.001).There was no statistically significant difference in the total effective rates of the Nitro and Bevar groups(P>0.05);The degree of tumor volume reduction and SCC reduction in the Nituo group and Bevac group after treatment was higher than those in the control group(P<0.05),and there was no statistically significant difference between the two groups(P>0.05).The incidence of hypertension in the Bevar group was 33.4%,significantly higher than that in the control group(10.0%)and the Nitro group(12.9%)(P<0.05).There was no statistically significant difference in the incidence of hypertension between the Nito group and the control group(P>0.05);There was no statistically significant difference in the incidence of adverse reactions among the three groups excep
作者
薛良方
王欣舒
张云艳
成海燕
靳红
王耀先
杨珊珊
李奇
XUE Liangfang;WANG Xinshu;ZHANG Yunyan;CHENG Haiyan;JIN Hong;WANG Yaoxian;YANG Shanshan;LI Qi(Department of Gynecologic Radiotherapy,Harbin Medical University Cancer Hospital,Harbin 150081,China;Department of Medicine,Nantong University)
出处
《实用肿瘤学杂志》
CAS
2023年第5期416-421,共6页
Practical Oncology Journal
基金
哈尔滨医科大学附属肿瘤医院海燕基金项目(编号:JJZD2021-16)。
关键词
宫颈癌
局部晚期
尼妥珠单抗
贝伐珠单抗
同步放化疗
Cervical cancer
Locally advanced
Nituzumab
Bevacizumab
Synchronous radiotherapy and chemotherapy
